Is there a gender effect in polycythemia vera?

1.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544CrossRefPubMed

2.

Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working Group for Myelofibrosis Research and Treatment. Leukemia 22(2):437–438. https://doi.org/10.1038/sj.leu.2404914PubMedCrossRef

3.

Titmarsh GJ, Duncombe AS, McMullin MF, O’Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA (2014) How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 89(6):581–587. https://doi.org/10.1002/ajh.23690PubMedCrossRef

4.

McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, S SK, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Mead AJ (2019) A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology guideline. Br J Haematol 184(2):176–191. https://doi.org/10.1111/bjh.15648PubMedCrossRef

5.

Spivak JL (2019) How I treat polycythemia vera. Blood 134(4):341–352. https://doi.org/10.1182/blood.2018834044PubMedCrossRef

6.

Passamonti F (2012) How to manage polycythemia vera. Leukemia 26(5):870–874. https://doi.org/10.1038/leu.2011.334PubMedCrossRef

7.

Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124(16):2507–2513; quiz 2615. https://doi.org/10.1182/blood-2014-05-579136PubMedPubMedCentralCrossRef

8.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332PubMedCrossRef

9.

Ratajczak MZ (2017) Why are hematopoietic stem cells so ‘sexy’? On a search for developmental explanation. Leukemia 31(8):1671–1677. https://doi.org/10.1038/leu.2017.148PubMedPubMedCentralCrossRef

10.

Kim HI, Lim H, Moon A (2018) Sex differences in cancer: epidemiology, genetics and therapy. Biomol Ther 26(4):335–342. https://doi.org/10.4062/biomolther.2018.103CrossRef

11.

Bolufer P, Collado M, Barragan E, Cervera J, Calasanz MJ, Colomer D, Roman-Gomez J, Sanz MA (2007) The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica 92(3):308–314. https://doi.org/10.3324/haematol.10752PubMedCrossRef

12.

Do TN, Ucisik-Akkaya E, Davis CF, Morrison BA, Dorak MT (2010) An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males. Biochim Biophys Acta 1802(2):292–300. https://doi.org/10.1016/j.bbadis.2009.10.015PubMedCrossRef

13.

Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119(14):3276–3284. https://doi.org/10.1182/blood-2011-09-380949PubMedCrossRef

14.

Riihijarvi S, Taskinen M, Jerkeman M, Leppa S (2011) Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 86(2):124–128. https://doi.org/10.1111/j.1600-0609.2010.01541.xPubMedCrossRef

15.

Wang J, Huang Y (2007) Pharmacogenomics of sex difference in chemotherapeutic toxicity. Current drug discovery technologies 4(1):59–68. https://doi.org/10.2174/157016307781115485PubMedCrossRef

16.

Tran C, Knowles SR, Liu BA, Shear NH (1998) Gender differences in adverse drug reactions. J Clin Pharmacol 38(11):1003–1009. https://doi.org/10.1177/009127009803801103PubMedCrossRef

17.

Fattinger K, Roos M, Vergères P, Holenstein C, Kind B, Masche U, Stocker DN, Braunschweig S, Kullak-Ublick GA, Galeazzi RL, Follath F, Gasser T, Meier PJ (2000) Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 49(2):158–167. https://doi.org/10.1046/j.1365-2125.2000.00132.xPubMedPubMedCentralCrossRef

18.

Anderson GD (2005) Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. Journal of women’s health (2002) 14(1):19–29. https://doi.org/10.1089/jwh.2005.14.19CrossRef

19.

Murphy WG (2014) The sex difference in haemoglobin levels in adults - mechanisms, causes, and consequences. Blood Rev 28(2):41–47. https://doi.org/10.1016/j.blre.2013.12.003PubMedCrossRef

20.

Shahani S, Braga-Basaria M, Maggio M, Basaria S (2009) Androgens and erythropoiesis: past and present. J Endocrinol Investig 32(8):704–716. https://doi.org/10.1007/bf03345745CrossRef

21.

Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M, Connor Westfall J, Bae H, Gordeuk V, Bhasin S (2014) Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci 69(6):725–735. https://doi.org/10.1093/gerona/glt154PubMedCrossRef

22.

Handelsman DJ, Hirschberg AL, Bermon S (2018) Circulating testosterone as the hormonal basis of sex differences in athletic performance. Endocr Rev 39(5):803–829. https://doi.org/10.1210/er.2018-00020PubMedPubMedCentralCrossRef

23.

Cook JD, Flowers CH, Skikne BS (2003) The quantitative assessment of body iron. Blood 101(9):3359–3364. https://doi.org/10.1182/blood-2002-10-3071PubMedCrossRef

24.

Yip R, Johnson C, Dallman PR (1984) Age-related changes in laboratory values used in the diagnosis of anemia and iron deficiency. Am J Clin Nutr 39(3):427–436. https://doi.org/10.1093/ajcn/39.3.427PubMedCrossRef

25.

Vahlquist B (1950) The cause of the sexual differences in erythrocyte hemoglobin and serum iron levels in human adults. Blood 5(9):874–875PubMedCrossRef

26.

Garn SM, Smith NJ, Clark DC (1975) Lifelong differences in hemoglobin levels between blacks and whites. J Natl Med Assoc 67(2):91–96PubMedPubMedCentral

27.

Tilling L, Hunt J, Jiang B, Sanders TA, Clapp B, Chowienczyk P (2013) Endothelial function does not relate to haemoglobin or serum erythropoietin concentrations and these do not explain the gender difference in endothelial function in healthy middle-aged men and women. Eur J Clin Investig 43(3):225–230. https://doi.org/10.1111/eci.12033CrossRef

28.

Pearson TC, Messinezy M (1996) The diagnostic criteria of polycythaemia rubra vera. Leukemia & lymphoma 22(Suppl 1):87–93

29.

Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100(7):2292–2302. https://doi.org/10.1182/blood-2002-04-1199PubMedCrossRef

30.

Tefferi A, Thiele J, Vardiman JW (2009) The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 115(17):3842–3847. https://doi.org/10.1002/cncr.24440PubMedCrossRef

31.

Berlin NI (1975) Diagnosis and classification of the polycythemias. Semin Hematol 12(4):339–351PubMed

32.

Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR (1986) Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol 23(2):132–143PubMed

33.

Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of the polycythemia Vera study group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34(1):29–39PubMed

34.

Pierre R, Imbert M, Thiele J et al (2001) Tumours of haematopoietic and lymphoid tissues. IARC Press, London

35.

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937–951. https://doi.org/10.1182/blood-2009-03-209262PubMedCrossRef

36.

Lussana F, Carobbio A, Randi ML, Elena C, Rumi E, Finazzi G, Bertozzi I, Pieri L, Ruggeri M, Palandri F, Polverelli N, Elli E, Tieghi A, Iurlo A, Ruella M, Cazzola M, Rambaldi A, Vannucchi AM, Barbui T (2014) A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. Br J Haematol 167(4):541–546. https://doi.org/10.1111/bjh.13080PubMedCrossRef

37.

Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ (2013) Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 122(11):1881–1886. https://doi.org/10.1182/blood-2013-06-508416PubMedCrossRef

38.

Sant’Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Iurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM (2020) Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases. Am J Hematol 95(2):156–166. https://doi.org/10.1002/ajh.25677PubMedCrossRef

39.

Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (2014) Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 92(4):289–297. https://doi.org/10.1111/ejh.12256PubMedCrossRef

40.

Landolfi R, Di Gennaro L, Nicolazzi MA, Giarretta I, Marfisi R, Marchioli R (2012) Polycythemia vera: gender-related phenotypic differences. Intern Emerg Med 7(6):509–515. https://doi.org/10.1007/s11739-011-0634-3PubMedCrossRef

41.

McNally RJ, Rowland D, Roman E, Cartwright RA (1997) Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 15(4):173–189. https://doi.org/10.1002/(sici)1099-1069(199711)15:4<173::aid-hon610>3.0.co;2-kPubMedCrossRef

42.

Cartwright RA, Gurney KA, Moorman AV (2002) Sex ratios and the risks of haematological malignancies. Br J Haematol 118(4):1071–1077. https://doi.org/10.1046/j.1365-2141.2002.03750.xPubMedCrossRef

43.

Deadmond MA, Smith-Gagen JA (2015) Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. J Cancer Res Clin Oncol 141(12):2131–2138. https://doi.org/10.1007/s00432-015-1983-5PubMedCrossRef

44.

Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350(2):114–124. https://doi.org/10.1056/NEJMoa035572PubMedCrossRef

45.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22–33. https://doi.org/10.1056/NEJMoa1208500PubMedCrossRef

46.

Passamonti F, Malabarba L, Orlandi E, Barate C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M (2003) Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 88(1):13–18PubMed

47.

Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, KA (eds) C SEER Cancer Statistics Review, 1975–2016. National Cancer Institute B ethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019

48.

Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, Spivak JL, Moliterno AR (2010) Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 95(7):1090–1097. https://doi.org/10.3324/haematol.2009.014407PubMedPubMedCentralCrossRef

49.

Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24(9):1574–1579. https://doi.org/10.1038/leu.2010.148PubMedCrossRef

50.

Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70–87. https://doi.org/10.1016/j.blre.2019.04.005PubMedCrossRef

51.

Jayasuriya NA, Kjaergaard AD, Pedersen KM, Sørensen AL, Bak M, Larsen MK, Nordestgaard BG, Bojesen SE, Çolak Y, Skov V, Kjaer L, Tolstrup JS, Hasselbalch HC, Ellervik C (2020) Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people. Br J Haematol 189(2):323–334. https://doi.org/10.1111/bjh.16321PubMedCrossRef

52.

Marneth AE, Mullally A (2020) The molecular genetics of myeloproliferative neoplasms. Cold Spring Harbor perspectives in medicine 10(2). https://doi.org/10.1101/cshperspect.a034876

53.

Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, Sordi B, Szuber N, Rotunno G, Pacilli A, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Vannucchi AM (2020) Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. British journal of haematology. doi:https://doi.org/10.1111/bjh.16380

54.

Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M (2011) Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 117(10):2813–2816. https://doi.org/10.1182/blood-2010-11-316810PubMedCrossRef

55.

Tefferi A, Lavu S, Mudireddy M, Lasho TL, Finke CM, Gangat N, Pardanani A, Hanson CA, Mannarelli C, Guglielmelli P, Vannucchi AM (2018) JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. Am J Hematol 93(4):E93–e96. https://doi.org/10.1002/ajh.25017PubMedCrossRef

56.

Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL (2007) The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 21(10):2210–2212. https://doi.org/10.1038/sj.leu.2404755PubMedCrossRef

57.

Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, Scapin M, Arcaini L, Tezza F, Moratti R, Pascutto C, Fabris F, Morra E, Cazzola M, Lazzarino M (2007) Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 110(2):485–489. https://doi.org/10.1182/blood-2007-01-071068PubMedCrossRef

58.

Kiladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N, Conejero C, Briere J, Fenaux P, Chomienne C, Grandchamp B (2006) Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia 20(6):1181–1183. https://doi.org/10.1038/sj.leu.2404214PubMedCrossRef

59.

Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC (2006) Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108(4):1377–1380. https://doi.org/10.1182/blood-2005-11-009605PubMedCrossRef

60.

Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S, Prchal JF, Prchal JT (2007) Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35(1):32–38. https://doi.org/10.1016/j.exphem.2006.11.012PubMedCrossRef

61.

Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, Pacilli A, Hanson CA, Pancrazzi A, Ketterling RP, Mannarelli C, Barraco D, Fanelli T, Pardanani A, Gangat N, Vannucchi AM (2016) Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood advances 1(1):21–30. https://doi.org/10.1182/bloodadvances.2016000216PubMedPubMedCentralCrossRef

62.

Karantanos T, Chaturvedi S, Braunstein EM, Spivak J, Resar L, Karanika S, Williams DM, Rogers O, Gocke CD, Moliterno AR (2020) Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood advances 4(12):2567–2576. https://doi.org/10.1182/bloodadvances.2019001407PubMedPubMedCentralCrossRef

63.

Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE (2013) Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49488 individuals from the general population. Br J Haematol 160(1):70–79. https://doi.org/10.1111/bjh.12099PubMedCrossRef

64.

Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS (2014) JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica 99(9):1448–1455. https://doi.org/10.3324/haematol.2014.107631PubMedPubMedCentralCrossRef

65.

Spivak JL, Considine M, Williams DM, Talbot CC Jr, Rogers O, Moliterno AR, Jie C, Ochs MF (2014) Two clinical phenotypes in polycythemia vera. N Engl J Med 371(9):808–817. https://doi.org/10.1056/NEJMoa1403141PubMedPubMedCentralCrossRef

66.

Barraco D, Cerquozzi S, Hanson CA, Ketterling RP, Pardanani AD, Gangat N, Tefferi A (2018) Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. Br J Haematol 182(3):437–440. https://doi.org/10.1111/bjh.14798PubMedCrossRef

67.

Tang G, Hidalgo Lopez JE, Wang SA, Hu S, Ma J, Pierce S, Zuo W, Carballo-Zarate AA, Yin CC, Tang Z, Li S, Medeiros LJ, Verstovsek S, Bueso-Ramos CE (2017) Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica 102(9):1511–1518. https://doi.org/10.3324/haematol.2017.165795PubMedPubMedCentralCrossRef

68.

Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A (2011) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96(2):315–318. https://doi.org/10.3324/haematol.2010.031070PubMedCrossRef

69.

Stein BL, Rademaker A, Spivak JL, Moliterno AR (2011) Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis 2011:874146. https://doi.org/10.1155/2011/874146PubMedPubMedCentralCrossRef

70.

De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Barbui T (2016) Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood cancer journal 6(11):e493. https://doi.org/10.1038/bcj.2016.103PubMedPubMedCentralCrossRef

71.

Lavu S, Szuber N, Mudireddy M, Yogarajah M, Gangat N, Pardanani A, Hanson CA, Ketterling RP, Ashrani AA, Kamath PS, Tefferi A (2018) Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo clinic experience with 84 consecutive cases. Am J Hematol 93(3):E61–e64. https://doi.org/10.1002/ajh.24993PubMedCrossRef

72.

Alvarez-Larran A, Pereira A, Magaz M, Hernandez-Boluda JC, Garrote M, Cuevas B, Ferrer-Marin F, Gomez-Casares MT, Garcia-Gutierrez V, Mata-Vazquez MI, Turon F, Hernandez-Gea V, Arellano-Rodrigo E, Cervantes F, Garcia-Pagan JC (2020) Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. Ann Hematol 99(4):791–798. https://doi.org/10.1007/s00277-020-03965-zPubMedCrossRef

73.

De Stefano V, Za T, Ciminello A, Betti S, Rossi E (2011) Causes of adult splanchnic vein thrombosis in the mediterranean area. Mediterranean journal of hematology and infectious diseases 3(1):e2011063. https://doi.org/10.4084/mjhid.2011.063PubMedPubMedCentralCrossRef

74.

Janssen HL, Wijnhoud A, Haagsma EB, van Uum SH, van Nieuwkerk CM, Adang RP, Chamuleau RA, van Hattum J, Vleggaar FP, Hansen BE, Rosendaal FR, van Hoek B (2001) Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 49(5):720–724. https://doi.org/10.1136/gut.49.5.720PubMedPubMedCentralCrossRef

75.

Denninger MH, Chaït Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D (2000) Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology (Baltimore, Md) 31(3):587–591. https://doi.org/10.1002/hep.510310307CrossRef

76.

Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benhamou JP (1986) Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 90(4):807–811. https://doi.org/10.1016/0016-5085(86)90855-3PubMedCrossRef

77.

Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR (2000) Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 96(7):2364–2368PubMed

78.

Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111(10):4922–4929. https://doi.org/10.1182/blood-2007-11-125328PubMedCrossRef

79.

Qi X, Ren W, De Stefano V, Fan D (2014) Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 12 (11):1801–1812.e1807. doi:https://doi.org/10.1016/j.cgh.2014.04.026

80.

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30(33):4098–4103. https://doi.org/10.1200/jco.2012.42.3863CrossRef

81.

Barbui T, Masciulli A, Marfisi MR, Tognoni G, Finazzi G, Rambaldi A, Vannucchi A (2015) White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood 126(4):560–561. https://doi.org/10.1182/blood-2015-04-638593PubMedCrossRef

82.

Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N, Thiele J, Buske C (2015) Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology 26(Suppl 5):v85–v99. https://doi.org/10.1093/annonc/mdv203CrossRef

83.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057–1069. https://doi.org/10.1038/s41375-018-0077-1PubMedPubMedCentralCrossRef

84.

Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y (1995) Interpretation of measured red cell mass and plasma volume in adults: expert panel on radionuclides of the International Council for Standardization in Haematology. Br J Haematol 89(4):748–756. https://doi.org/10.1111/j.1365-2141.1995.tb08411.xPubMedCrossRef

85.

Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barosi G (2018) Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia 32(9):2077–2081. https://doi.org/10.1038/s41375-018-0199-5PubMedCrossRef

86.

Kander EM, Moliterno AR, Rademaker A, Streiff MB, Spivak JL, Stein BL (2016) Practice patterns in the diagnosis and treatment of polycythemia vera in the post-JAK2 V617F discovery era. Journal of the National Comprehensive Cancer Network : JNCCN 14(10):1238–1245. https://doi.org/10.6004/jnccn.2016.0133PubMedCrossRef

87.

Grunwald MR, Kuter DJ, Altomare I, Burke JM, Gerds AT, Walshauser MA, Savona MR, Stein B, Oh ST, Colucci P, Parasuraman S, Paranagama D, Mesa R (2019) Treatment patterns and blood counts in patients with polycythemia vera treated with hydroxyurea in the United States: an analysis from the REVEAL study. Clinical lymphoma, myeloma & leukemia. https://doi.org/10.1016/j.clml.2019.09.601

88.

Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148(6):961–963. https://doi.org/10.1111/j.1365-2141.2009.08019.xPubMedCrossRef

89.

Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, Perez-Encinas M, Ferrer-Marin F, Barez A, Martinez-Lopez J, Cuevas B, Mata MI, Garcia-Gutierrez V, Aragues P, Montesdeoca S, Burgaleta C, Caballero G, Hernandez-Rivas JA, Duran MA, Gomez-Casares MT, Besses C (2016) Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol 172(5):786–793. https://doi.org/10.1111/bjh.13886PubMedCrossRef

90.

Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426–435. https://doi.org/10.1056/NEJMoa1409002PubMedPubMedCentralCrossRef

91.

Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. The Lancet Oncology 18(1):88–99. https://doi.org/10.1016/s1470-2045(16)30558-7PubMedCrossRef

92.

Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ (2016) Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 101(7):821–829. https://doi.org/10.3324/haematol.2016.143644PubMedPubMedCentralCrossRef

93.

Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F (2018) Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol 97(9):1591–1600. https://doi.org/10.1007/s00277-018-3365-yPubMedPubMedCentralCrossRef

94.

Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Coltro G, Guglielmelli P, Vannucchi AM (2017) Gender and survival in essential thrombocythemia: a two-center study of 1494 patients. Am J Hematol 92(11):1193–1197. https://doi.org/10.1002/ajh.24882PubMedCrossRef

95.

Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117(10):755–761. https://doi.org/10.1016/j.amjmed.2004.06.032PubMedCrossRef

96.

Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105(7):2664–2670. https://doi.org/10.1182/blood-2004-09-3426PubMedCrossRef

97.

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Mullauer L, Pardanani A, Thiele J, Passamonti F, Barbui T (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874–1881. https://doi.org/10.1038/leu.2013.163PubMedPubMedCentralCrossRef

98.

Alvarez-Larran A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernandez-Boluda JC, Ferrer-Marin F, Angona A, Gomez M, Muina B, Guillen H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119(6):1363–1369. https://doi.org/10.1182/blood-2011-10-387787PubMedCrossRef

99.

Cerquozzi S, Tefferi A (2015) Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood cancer journal 5:e366. https://doi.org/10.1038/bcj.2015.95PubMedPubMedCentralCrossRef

100.

Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A (2007) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 31(6):737–740. https://doi.org/10.1016/j.leukres.2006.12.002PubMedCrossRef

101.

Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, Caramazza D, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM (2017) Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia 31(4):970–973. https://doi.org/10.1038/leu.2016.351PubMedCrossRef

102.

Yogarajah M, Tefferi A (2017) Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin Proc 92(7):1118–1128. https://doi.org/10.1016/j.mayocp.2017.05.010PubMedCrossRef

103.

Beer PA, Delhommeau F, LeCouedic JP, Dawson MA, Chen E, Bareford D, Kusec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Green AR (2010) Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115(14):2891–2900. https://doi.org/10.1182/blood-2009-08-236596PubMedCrossRef

104.

Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD (2011) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol Off J Am Soc Clin Oncol 29(29):3907–3913. https://doi.org/10.1200/jco.2011.36.0792CrossRef

105.

Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23(10):2224–2232. https://doi.org/10.1200/jco.2005.07.062CrossRef

106.

Bjorkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegard G, Linder O, Malm C, Markevarn B, Nilsson L, Samuelsson J, Granath F, Landgren O (2011) Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29(17):2410–2415. https://doi.org/10.1200/jco.2011.34.7542CrossRef

107.

Bai J, Ai L, Zhang L, Yang FC, Zhou Y, Xue Y (2015) Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. Am J Hematol 90(12):1116–1121. https://doi.org/10.1002/ajh.24191PubMedCrossRef

108.

Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110(3):840–846. https://doi.org/10.1182/blood-2006-12-064287PubMedCrossRef

109.

Bonora M, Wieckowsk MR, Chinopoulos C, Kepp O, Kroemer G, Galluzzi L, Pinton P (2015) Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. Oncogene 34(12):1608. https://doi.org/10.1038/onc.2014.462PubMedCrossRef

110.

Cuthbert D, Stein BL (2019) Therapy-associated leukemic transformation in myeloproliferative neoplasms - what do we know? Best Pract Res Clin Haematol 32(1):65–73. https://doi.org/10.1016/j.beha.2019.02.004PubMedCrossRef

111.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F (2018) Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood cancer journal 8(10):89. https://doi.org/10.1038/s41408-018-0128-xPubMedPubMedCentralCrossRef

112.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F (2018) Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica 103(9):e392–e394. https://doi.org/10.3324/haematol.2017.185751PubMedPubMedCentralCrossRef

113.

Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN (2005) The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica 90(11):1477–1483PubMed

114.

Alimam S, Bewley S, Chappell LC, Knight M, Seed P, Gray G, Harrison C, Robinson S (2016) Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol 175(1):31–36. https://doi.org/10.1111/bjh.14289PubMedCrossRef

115.

Bertozzi I, Rumi E, Cavalloni C, Cazzola M, Fabris F, Randi ML (2018) Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera. Am J Hematol 93(9):E234–e235. https://doi.org/10.1002/ajh.25210PubMedCrossRef

116.

Maze M, Kazi S, Gupta V, Malinowski A, Fazelzad R, Shah P, Shehata N (2018) Pregnancy outcomes in patients with myeloproliferative neoplasms: a systematic review and meta-analysis. Blood 132:3046. https://doi.org/10.1182/blood-2018-99-118299CrossRef

117.

Elli EM, Diral E, Gambacorti-Passerini C, Calori R, Carmosino I, Breccia M, Latagliata R, Di Veroli A (2019) Management and outcome of 11 pregnancies in women with polycythemia vera. Leuk Res 81:25–26. https://doi.org/10.1016/j.leukres.2019.04.003PubMedCrossRef

118.

Gangat N, Wolanskyj AP, Schwager S, Tefferi A (2009) Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol 82(5):350–353. https://doi.org/10.1111/j.1600-0609.2009.01214.xPubMedCrossRef

119.

Rumi E, Bertozzi I, Casetti IC, Roncoroni E, Cavalloni C, Bellini M, Sant’Antonio E, Gotti M, Ferretti VV, Milanesi C, Peroni E, Pietra D, Astori C, Randi ML, Cazzola M (2015) Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia. Haematologica 100(11):e443–e445. https://doi.org/10.3324/haematol.2015.131458PubMedPubMedCentralCrossRef

120.

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29(6):761–770. https://doi.org/10.1200/jco.2010.31.8436CrossRef

121.

Robinson SE, Harrison CN (2020) How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy. Br J Haematol. https://doi.org/10.1111/bjh.16453

122.

Puyade M, Cayssials E, Pierre F, Pourrat O (2017) Pregnancy and myeloproliferative neoplasms : a retrospective monocentric cohort. Obstetric medicine 10(4):165–169. https://doi.org/10.1177/1753495x17708896PubMedPubMedCentralCrossRef

123.

Griesshammer M, Struve S, Barbui T (2008) Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev 22(5):235–245. https://doi.org/10.1016/j.blre.2008.03.007PubMedCrossRef

124.

Beauverd Y, Radia D, Cargo C, Knapper S, Drummond M, Pillai A, Harrison C, Robinson S (2016) Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica 101(5):e182–e184. https://doi.org/10.3324/haematol.2015.139691PubMedPubMedCentralCrossRef

125.

Perez-Encinas M, Bello JL, Perez-Crespo S, De Miguel R, Tome S (1994) Familial myeloproliferative syndrome. Am J Hematol 46(3):225–229. https://doi.org/10.1002/ajh.2830460312PubMedCrossRef

126.

Aliverti V, Bonanomi L, Giavini E (1980) Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats. Archives of toxicology supplement = Archiv fur Toxikologie supplement 4:239-247

127.

Wright CA, Tefferi A (2001) A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 66(3):152–159. https://doi.org/10.1034/j.1600-0609.2001.00367.xPubMedCrossRef

128.

Datta P, Rewers-Felkins K, Kallem RR, Baker T, Hale TW (2017) Transfer of low dose aspirin into human milk. Journal of human lactation : official journal of International Lactation Consultant Association 33(2):296–299. https://doi.org/10.1177/0890334417695207CrossRef

129.

Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M (2018) Oral contraceptives and HRT risk of thrombosis. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 24(2):217–225. https://doi.org/10.1177/1076029616683802CrossRef

130.

Pinkerton JV, James AH (2018) Management of menopausal symptoms for women who are at high risk of thrombosis. Clin Obstet Gynecol 61(2):260–268. https://doi.org/10.1097/grf.0000000000000358PubMedCrossRef

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Is there a gender effect in polycythemia vera?

Abstract

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

An atypical chronic neutrophilic leukemia patient harboring ASXL1 and NRAS mutations associated with monoclonal plasma cell dyscrasia presenting as hemopericardium

Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

Correction to: Eltrombopag is effective in patients with relapse/refractory aplastic anemia—report from a single center in China

Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia

Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation

Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials